安图生物
(603658)
| 流通市值：213.37亿 | | | 总市值：213.37亿 |
| 流通股本：5.71亿 | | | 总股本：5.71亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 995,933,663.32 | 4,471,202,509.22 | 3,380,035,059.48 | 2,207,103,914.63 |
| 营业收入 | 995,933,663.32 | 4,471,202,509.22 | 3,380,035,059.48 | 2,207,103,914.63 |
| 二、营业总成本 | 746,443,403.96 | 3,307,150,305.92 | 2,408,355,902.26 | 1,583,246,923.9 |
| 营业成本 | 347,853,931.15 | 1,546,573,971.03 | 1,153,825,249.86 | 764,394,036.83 |
| 税金及附加 | 11,685,533.86 | 48,316,292.22 | 35,859,085.1 | 21,798,912.94 |
| 销售费用 | 195,260,976.79 | 767,766,504.11 | 551,539,143.37 | 368,582,706.27 |
| 管理费用 | 58,570,851.1 | 210,881,373.71 | 148,095,505.61 | 91,426,520.73 |
| 研发费用 | 130,563,085.75 | 731,932,785.27 | 511,265,272.32 | 333,232,807.55 |
| 财务费用 | 2,509,025.31 | 1,679,379.58 | 7,771,646 | 3,811,939.58 |
| 其中:利息费用 | 5,583,446.15 | 22,281,972.04 | 16,950,785.02 | 11,625,874.44 |
| 其中:利息收入 | 1,017,384.07 | 20,565,513.62 | 10,878,628.18 | 9,302,802.12 |
| 加:公允价值变动收益 | 649,979.05 | 3,609,780.75 | 10,703,146.14 | 7,035,162.86 |
| 加:投资收益 | 23,449,847.26 | 92,272,195.9 | 58,946,984.29 | 38,094,731.87 |
| 资产处置收益 | 37,110.02 | -1,169,696.21 | -1,168,868.83 | 1,334.78 |
| 资产减值损失(新) | 402,957.8 | -62,954,217.56 | -7,026,352.72 | -7,323,484.6 |
| 信用减值损失(新) | 9,988,165.74 | -55,606,118.47 | -34,952,874.19 | -15,665,898.88 |
| 其他收益 | 19,480,632.72 | 105,284,799.74 | 65,920,794.8 | 43,101,208.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 303,498,951.95 | 1,245,488,947.45 | 1,064,101,986.71 | 689,100,045.54 |
| 加:营业外收入 | 1,264,348.54 | 62,790,815.15 | 4,151,257.69 | 3,023,712.48 |
| 减:营业外支出 | 2,624,860.36 | 19,223,288.41 | 13,977,192.9 | 4,938,201.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 302,138,440.13 | 1,289,056,474.19 | 1,054,276,051.5 | 687,185,556.26 |
| 减:所得税费用 | 29,058,717.66 | 89,823,194.3 | 84,843,418.23 | 60,208,317.18 |
| 六、净利润 | 273,079,722.47 | 1,199,233,279.89 | 969,432,633.28 | 626,977,239.08 |
| 持续经营净利润 | 273,079,722.47 | 1,199,233,279.89 | 969,432,633.28 | 626,977,239.08 |
| 归属于母公司股东的净利润 | 269,880,235.57 | 1,194,451,909.72 | 956,174,546.82 | 619,513,343.19 |
| 少数股东损益 | 3,199,486.9 | 4,781,370.17 | 13,258,086.46 | 7,463,895.89 |
| (一)基本每股收益 | 0.47 | 2.07 | 1.65 | 1.09 |
| (二)稀释每股收益 | 0.47 | 2.07 | 1.65 | 1.09 |
| 八、其他综合收益 | -12,112 | 106,410.67 | -138,346.28 | 70,245.37 |
| 归属于母公司股东的其他综合收益 | -12,112 | 106,410.67 | -138,346.28 | 70,245.37 |
| 九、综合收益总额 | 273,067,610.47 | 1,199,339,690.56 | 969,294,287 | 627,047,484.45 |
| 归属于母公司股东的综合收益总额 | 269,868,123.57 | 1,194,558,320.39 | 956,036,200.54 | 619,583,588.56 |
| 归属于少数股东的综合收益总额 | 3,199,486.9 | 4,781,370.17 | 13,258,086.46 | 7,463,895.89 |
| 公告日期 | 2025-04-18 | 2025-04-18 | 2024-10-26 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |